Blood or Marrow? MRD poster presented at ESH AML Conference

Rarity Bioscience’s Alexander Kele and Ann-Sofi Johansson attended the biannual ESH AML Conference, in Estoril (Portugal). They were there not only to discuss MRD testing but also to support the poster presentation “Utility of Blood vs Bone marrow for molecular MRD in AML and MDS”. 

Anna Robelius presenting at ESH

”We are grateful to Anna Robelius (Hematology specialist at Uppsala University Hospital) for such an interesting presentation of both her clinical work and the superRCA technology”

Ann-Sofi Johansson

Product Development Manager

Rarity Bioscience

”It’s been an interesting conference all through and I am grateful to the organizers for pulling together scientists across the board from basic research to cancer biology, in vivo and clinical studies.”

 

Alexander Kele

 

Product Development Manager, Rarity Bioscience

Share this article

Recommended articles

Rarity Bioscience at the CYTO 2024 Conference

Rarity Bioscience’s Linus Bosaeus and Lei Chen was at the CYTO 2024 Conference in Edinburgh, to present the study Ultra-sensitive Molecular MRD on Flow Cytometer using superRCA Mutation Assay, showcasing our new ultra-sensitive mutation detection technology superRCA.

Read more »

Rarity Bioscience at the Nordic Precision Medicine Forum

Rarity Bioscience was at the Nordic Precision Medicine Forum, presenting an engaging study that highlights the latest advancements in precision oncology: ”Ultra-sensitive Monitoring of Minimal Residual Disease (MRD) for Cancer Patients, using superRCA Mutation Assays with Flow Cytometry Readout”

Read more »